» Articles » PMID: 24291374

Serum Levels of CEA and CA15-3 in Different Molecular Subtypes and Prognostic Value in Chinese Breast Cancer

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2013 Dec 3
PMID 24291374
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

The prognostic significance of preoperative carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in breast cancer is controversial. This study evaluated the prognostic value of preoperative serum CEA and CA15-3 levels in Chinese breast cancer patients. A total of 470 patients with breast cancer had preoperative CEA and CA15-3 concentrations measured. The relationships between preoperative concentration and clinicopathological factors and outcomes were determined. CEA and CA15-3 levels were increased in 34 (7.2%) and 58 (12.3%) patients, respectively. Elevations of serum CEA and CA-15-3 levels correlated with the primary tumor size and axillary lymph node status. CEA levels were lower in patients with triple-negative breast cancer than in those with other subtypes (P = 0.002). The 5-year distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) of CEA-negative vs. CEA-positive patients were 84.1% vs. 54.5% (P < 0.001), 82.7% vs. 54.8% (P < 0.001), and 89.7% vs. 78.5% (P = 0.007), respectively. The 5-year DMFS, DFS, and OS of CA15-3-negative vs. CA15-3-positive patients were 84.0% vs. 69.6% (P = 0.002), 83.0% vs. 66.2% (P < 0.001), 90.9% vs. 74.2% (P = 0.005), respectively. Multivariate analysis of prognosis indicated that CEA and CA15-3 levels were independent prognostic factors for DMFS (P = 0.021) and DFS (P = 0.032), and DFS (P = 0.014) and OS (P = 0.032), respectively. Serum levels of CEA and CA15-3 may differ in breast cancer molecular subtypes and preoperative levels of CEA and CA15-3 have a significant effect on prognosis in Chinese women with breast cancer.

Citing Articles

Robust anticancer efficacy of venom-loaded silica nanoparticles against triple-negative breast cancer xenografts in a preclinical rat model.

Soliman N, Shalaby A, Mohamed H, Abdelkarem Alashqar S, Ammar M Open Vet J. 2025; 14(12):3552-3562.

PMID: 39927364 PMC: 11799658. DOI: 10.5455/OVJ.2024.v14.i12.37.


The Effects of Preoperative Serum Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 on the Prognosis of Breast Cancer Patients With Different Molecular Subtypes.

Yilihamu Y, Wang L, Ma T, Zhao T, Wang Y, Sun G J Clin Med Res. 2024; 16(10):491-502.

PMID: 39544329 PMC: 11557502. DOI: 10.14740/jocmr5237.


Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer.

Abd ELhafeez A, Ghanem H, Swellam M, Taha A Cancer Biomark. 2024; 39(4):313-333.

PMID: 38250762 PMC: 11091646. DOI: 10.3233/CBM-230396.


Circulating tumor cells in peripheral blood as a diagnostic biomarker of breast cancer: A meta-analysis.

Jin T, Chen Y, Chen Q, Xiong Y, Yang J Front Oncol. 2023; 13:1103146.

PMID: 37035139 PMC: 10073650. DOI: 10.3389/fonc.2023.1103146.


Diagnostic role of heart rate variability in breast cancer and its relationship with peripheral serum carcinoembryonic antigen.

Ding L, Yang Y, Chi M, Chen Z, Huang Y, Ouyang W PLoS One. 2023; 18(4):e0282221.

PMID: 37023015 PMC: 10079040. DOI: 10.1371/journal.pone.0282221.